Entrada Therapeutics, Inc. (TRDA) SEC Filings & Earnings Calls

Early stage; dystrophin increase small; functional benefit not yet shown

“No observable functional benefit after three doses; dystrophin increase at low dose is modest.”

Accumulated deficit and going concern risk

“As of June 30, 2026, the Company had an accumulated deficit of $355.6 million.” · word for word

Dependence on Vertex collaboration

“Collaboration revenue declined significantly; future revenue depends on continued collaboration and milestone payments.”

Pre-revenue biotech with clinical-stage pipeline; no approved products

“No product revenue; collaboration revenue declining; cash burn rate ~$36M/quarter”

Clinical trial execution risk for multiple programs

“Multiple Phase 1/2 trials ongoing; data readouts in 2026-2027; FDA interactions pending for ELEVATE-44-102”

Potential shareholder dilution from increased shares available under equity plans.

“Amendments to evergreen provisions increase shares for issuance.”

Clinical trial risks for DMD pipeline, including potential failure or delays.

“uncertainties inherent in the identification and development of product candidates, including the conduct of research activities and the initiation and completion of clinical trials” · word for word

Dependence on collaboration revenue

“Collaboration revenue declined 95.7% YoY; company has no approved products.”

Significant operating losses

“Net loss $(39.7)M in Q1 2026; accumulated deficit $312.8M.”

Clinical development risk: subsequent cohorts and additional studies may not replicate positive results.

“Data from Cohort 1 open-label period and Cohort 2 (12 mg/kg) expected by year-end 2026; Cohort 3 (up to 18 mg/kg) to follow.”

Regulatory risk: FDA interaction needed to finalize design of ELEVATE-44-102 study in advanced DMD patients.

“Company plans to re-engage with the FDA to discuss increasing the planned doses in this clinical study.” · word for word

Dependence on partnership: VX-670 (DM1) program with Vertex; results expected H2 2026.

“Vertex continues to enroll and dose the MAD portion of the GALILEO global Phase 1/2 clinical study of VX-670... on track to share results during the second half of 2026.” · word for word

Clinical trial failure risk

“We have not completed the testing of any of our therapeutic candidates in clinical trials and our therapeutic candidates may not have favorable results in clinical trials, if any, or receive regulatory approval on a timely basis, if at all.” · word for word

Financing risk

“We will require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs” · word for word

Competition risk

“We face significant competition, and if our competitors develop technologies or therapeutic candidates more rapidly than we do or their technologies are more effective, our business and our ability to develop and successfully commercialize products may be adversely affected.” · word for word

Novel platform risk

“Our Endosomal Escape Vehicle (EEV) therapeutic candidates are based on a novel therapeutic approach, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval, if at all.” · word for word

Clinical trial failure risk for DMD programs

“The Company is on track to report data from Cohort 1 (6 mg/kg) in the second quarter of 2026... data from Cohort 2 (12 mg/kg) by year-end 2026.” · word for word

Revenue concentration risk from Vertex collaboration

“Collaboration revenue decreased significantly due to completion of VX-670 research activities.”

Cash burn rate risk

“Cash decreased from $420.0M to $295.7M year-over-year, with runway into Q3 2027.”

Cash burn rate high; collaboration revenue declining; net loss widening.

“Cash decreased from $420M to $326.8M; collaboration revenue down 91.8%; net loss increased to $44.1M.”

Clinical-stage company with no approved products; pipeline risk.

“All programs are in clinical trials; data readouts not until 2026.”

Dependence on collaboration revenue

“Collaboration revenue dropped from $19.6M to $1.6M year-over-year, indicating high volatility and dependence on milestone timing.”

No approved products

“The Company is a clinical-stage biopharmaceutical company with no commercial products and expects to continue generating operating losses.” · word for word